Glutamate: Molecular Mechanisms and Signaling Pathway in Alzheimer’s Disease, a Potential Therapeutic Target DOI Creative Commons
Nidhi Puranik, Minseok Song

Molecules, Год журнала: 2024, Номер 29(23), С. 5744 - 5744

Опубликована: Дек. 5, 2024

Gamma-glutamate is an important excitatory neurotransmitter in the central nervous system (CNS), which plays role transmitting synapses, plasticity, and other brain activities. Nevertheless, alterations glutamatergic signaling pathway are now accepted as a element Alzheimer's disease (AD) pathophysiology. One of most prevalent types dementia older adults AD, progressive neurodegenerative illness brought on by persistent decline cognitive function. Since AD has been shown to be multifactorial, variety pharmaceutical targets may used treat condition. N-methyl-D-aspartic acid receptor (NMDAR) antagonists acetylcholinesterase inhibitors (AChEIs) two drug classes that Food Drug Administration authorized for treatment AD. The AChEIs approved galantamine, donepezil, rivastigmine. However, memantine only non-competitive NMDAR antagonist This review aims outline involvement glutamate (GLU) at molecular level pathways associated with demonstrate target therapeutic potential its receptor. We will also consider opinion leading authorities working this area, drawback existing strategies, direction further investigation.

Язык: Английский

Assessment of Neuroprotective Potential of Cuscuta reflexa in Aluminium Chloride-Induced Experimental Model of Alzheimer’s Disease: In Vitro and In Vivo Studies DOI

Pallavi Gangarde,

Shvetank Bhatt, Rohini Pujari

и другие.

Journal of Trace Elements in Medicine and Biology, Год журнала: 2025, Номер 88, С. 127612 - 127612

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

2
Therapeutic Role of Heterocyclic Compounds in Neurodegenerative Diseases: Insights from Alzheimer’s and Parkinson’s Diseases DOI Creative Commons
Nidhi Puranik, Minseok Song

Neurology International, Год журнала: 2025, Номер 17(2), С. 26 - 26

Опубликована: Фев. 7, 2025

Alzheimer’s and Parkinson’s are the most common neurodegenerative diseases (NDDs). The development of aberrant protein aggregates progressive permanent loss neurons major characteristic features these disorders. Although precise mechanisms causing disease (AD) (PD) still unknown, there is a wealth evidence suggesting that misfolded proteins, accumulation dysfunction neuroreceptors mitochondria, dysregulation enzymes, release neurotransmitters significantly influence pathophysiology diseases. There no effective protective medicine or therapy available even with availability numerous medications. an urgent need to create new powerful bioactive compounds since number people NDDs rising globally. Heterocyclic have consistently played pivotal role in drug discovery due their exceptional pharmaceutical properties. Many clinically approved drugs, such as galantamine hydrobromide, donepezil hydrochloride, memantine opicapone, feature heterocyclic cores. As therapeutic potential, heterocycles intriguing research topic for drugs PD AD. This review aims provide current insights into potential use targeting diverse targets manage potentially treat patients AD PD.

Язык: Английский

Процитировано

1
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease DOI Creative Commons

Amin Mahmood Thawabteh,

Aseel Wasel Ghanem, Sara AbuMadi

и другие.

Molecules, Год журнала: 2024, Номер 29(21), С. 5131 - 5131

Опубликована: Окт. 30, 2024

The most prevalent chronic neurodegenerative illness in the world is Alzheimer's disease (AD). It results mental symptoms including behavioral abnormalities and cognitive impairment, which have a substantial financial psychological impact on relatives of patients. review discusses various pathophysiological mechanisms contributing to AD, amyloid beta, tau protein, inflammation, other factors, while emphasizing need for effective disease-modifying therapeutics that alter progression rather than merely alleviating symptoms. This mainly covers medications are now being studied clinical trials or recently approved by FDA fall under treatment (DMT) category, alters targeting underlying biological DMTs focus improving patient outcomes slowing decline, enhancing neuroprotection, supporting neurogenesis. Additionally, amyloid-targeting therapies, tau-targeting neuroprotective others. evaluation specifically looked at studies FDA-approved novel Phase II III development were carried out between 2021 2024. A thorough US government database identified biologics small molecule drugs 14 agents I, 34 II, 11 might be completed 2028.

Язык: Английский

Процитировано

8
Glutamate: Molecular Mechanisms and Signaling Pathway in Alzheimer’s Disease, a Potential Therapeutic Target DOI Creative Commons
Nidhi Puranik, Minseok Song

Molecules, Год журнала: 2024, Номер 29(23), С. 5744 - 5744

Опубликована: Дек. 5, 2024

Gamma-glutamate is an important excitatory neurotransmitter in the central nervous system (CNS), which plays role transmitting synapses, plasticity, and other brain activities. Nevertheless, alterations glutamatergic signaling pathway are now accepted as a element Alzheimer's disease (AD) pathophysiology. One of most prevalent types dementia older adults AD, progressive neurodegenerative illness brought on by persistent decline cognitive function. Since AD has been shown to be multifactorial, variety pharmaceutical targets may used treat condition. N-methyl-D-aspartic acid receptor (NMDAR) antagonists acetylcholinesterase inhibitors (AChEIs) two drug classes that Food Drug Administration authorized for treatment AD. The AChEIs approved galantamine, donepezil, rivastigmine. However, memantine only non-competitive NMDAR antagonist This review aims outline involvement glutamate (GLU) at molecular level pathways associated with demonstrate target therapeutic potential its receptor. We will also consider opinion leading authorities working this area, drawback existing strategies, direction further investigation.

Язык: Английский

Процитировано

6